AI governance in healthcare is the system of decisions, controls and evidence that keeps an AI use case aligned with its intended purpose. It tells a pharmacy, clinic or digital-health business who is accountable, which data may be used, where human judgement remains essential and what happens when performance changes or something goes wrong.
Buying an approved product or publishing an AI policy does not complete that work. Governance must continue through selection, configuration, deployment, staff use, monitoring, incident handling and retirement.
How should a healthcare organisation govern AI?
Maintain one inventory of AI use cases, assign accountable owners, define intended and prohibited uses, assess data and clinical risk, verify supplier evidence, keep meaningful human oversight and monitor real-world performance. Apply effort in proportion to the potential impact on people and care.
- Start with the decision or workflow, not the model name.
- Separate productivity tools from systems that influence clinical or patient-facing decisions.
- Keep an evidence trail from approval to monitoring, change and retirement.
Why AI governance matters now
AI features are appearing inside writing tools, search, call handling, documentation, analytics, customer support and clinical software. Some uses are low impact. Others can expose confidential information, introduce bias, alter patient communication or influence a decision that affects safety.
The GPhC’s April 2026 position statement on AI in pharmacy says pharmacy owners and superintendent pharmacists are expected to meet the Standards for registered pharmacies and supporting guidance when using AI. NHS England’s current AI information-governance guidance addresses lawful and safe use of data for AI in health and care.
The CQC’s 2026 statement on AI in health and social care describes its developing regulatory approach and points providers towards the AI and Digital Regulations Service. The MHRA also maintains guidance on software and AI as a medical device. These sources have different scopes; a governance process must identify which are relevant to the specific use case.
Begin with an AI inventory
You cannot govern tools you have not identified. Create a simple register covering approved, trialled and informally used AI. Include:
- the business or care problem and intended user;
- the AI function, supplier and product version;
- inputs, outputs and categories of data involved;
- whether patients or staff interact with the output;
- whether the output informs a clinical, operational, employment or commercial decision;
- the human review and escalation route;
- the accountable business, information-governance and clinical owners;
- approval, review and renewal dates; and
- dependencies, integrations and exit arrangements.
Include embedded features. A familiar software supplier may activate summarisation, prediction or generative functions inside an existing contract. That change can alter data flows and risk even when the product name stays the same.
Classify the use case before assessing the product
A practical first tier distinguishes impact:
Low-impact assistance
Examples may include drafting non-sensitive internal text or summarising public material, provided a person checks the output. Controls still need acceptable-use rules, approved accounts and protection against confidential data being pasted into unsuitable tools.
Operational or patient-facing support
Examples include call routing, service recommendations, personalised messages, demand forecasting or automated documentation. Errors may affect access, privacy, equality, records or trust. These uses need stronger testing, transparency, fallback and monitoring.
Clinical or safety-relevant influence
If AI contributes to diagnosis, prevention, monitoring, treatment or another medical purpose, specialist regulatory and clinical-safety assessment may be required. Do not rely on a marketing description. Define intended purpose and obtain qualified advice on whether medical-device requirements or other duties apply.
Use eight governance controls
1. Accountable ownership
Name one senior owner for the outcome and one operational owner for day-to-day control. Add clinical, data-protection, security and technical expertise in proportion to the risk. A supplier remains responsible for its obligations, but outsourcing technology does not outsource the provider’s responsibility for how it is selected and used.
2. Intended and prohibited use
Write a short intended-use statement: users, setting, task, inputs, output, decision supported and limitations. Then state prohibited uses. A transcription assistant, for example, should not quietly become a diagnostic adviser because staff discover it can generate suggestions.
3. Data governance
Map what data enters the system, why it is needed, where it goes, how long it remains and whether the supplier uses it to improve models. Establish lawful basis, transparency, access controls, retention and deletion. Where processing is likely to create high risk, complete a data protection impact assessment and resolve the risks before deployment. Pharmacy Mentor’s pharmacy cybersecurity guide covers the wider access, supplier and incident controls around digital services.
4. Clinical safety and regulation
Identify foreseeable hazards, affected users, existing controls and residual risk. NHS England’s digital clinical safety strategy explains the role of DCB0129, DCB0160 and DTAC in relevant NHS health-technology contexts. These frameworks are not a universal badge for every private tool, but their areas—clinical safety, data protection, technical security, interoperability, usability and accessibility—are useful assurance questions.
5. Supplier assurance
Request evidence, not adjectives. Ask about the training and evaluation data, known limitations, subgroup performance where relevant, security controls, hosting, subprocessors, incident history, model and feature changes, support, audit rights, service continuity and data return or deletion at exit. Record unanswered questions as risks.
6. Meaningful human oversight
Define what the reviewer must check, what information they need and when they must reject or escalate an output. A person clicking approve is not meaningful oversight if workload, interface design or missing context makes challenge unrealistic. Measure override and correction, not only completion.
7. Transparency and staff competence
Staff need role-specific training on permitted use, confidentiality, verification, bias, escalation and incident reporting. Patient-facing transparency should be clear enough for people to understand the role AI plays and how to ask questions or seek human support. Avoid broad assurances that imply the system is error-free.
8. Monitoring and change control
Set baseline measures before launch. Monitor errors, overrides, complaints, delays, subgroup differences, downtime, data incidents and unintended use. Reassess when the model, prompts, workflow, data source, integration or supplier terms change. Keep a route to pause the tool safely.
A proportionate approval pathway
- Propose: document the problem, intended use, expected benefit and alternatives.
- Triage: classify impact, data sensitivity, patient exposure and clinical influence.
- Assess: complete appropriate privacy, security, clinical-safety, equality, accessibility and supplier review.
- Test: use representative scenarios, known edge cases and failure conditions. Record the acceptance criteria.
- Approve: name the owners, controls, permitted users, training, review date and stop conditions.
- Deploy: start with a bounded pilot, fallback process and support route.
- Monitor: review performance, incidents, overrides, complaints and changes.
- Renew or retire: confirm the use still solves the original problem and remove access and data when it does not.
Common governance failures
- Shadow AI: staff use personal accounts because approved tools are unclear or impractical.
- Purpose drift: a low-risk assistant begins influencing higher-impact decisions.
- Policy without inventory: a document exists, but nobody knows which tools are live.
- Supplier evidence accepted uncritically: security or accuracy claims are not mapped to the actual configuration and users.
- Human review in name only: reviewers lack time, context or authority to challenge outputs.
- No change control: a model update alters behaviour without new testing.
- No exit plan: the organisation cannot retrieve data or continue the service when the tool fails.
What should owners do this month?
Ask every team to declare the AI tools and embedded features they use. Build the first inventory, prohibit confidential data in unapproved systems, choose one material use case for deeper review and assign owners. Test the incident and fallback route before expanding access.
For connected implementation support, explore Pharmacy Mentor’s pharmacy digital strategy, healthcare app development guide, pharmacy data analytics framework and pharmacy cybersecurity guidance. To map an AI-enabled workflow or product brief, book a Pharmacy Mentor consultation.
Frequently asked questions
What is AI governance in healthcare?
It is the set of ownership, policies, assessments, controls and evidence used to keep AI aligned with its intended purpose throughout selection, deployment, use, monitoring, change and retirement.
Does every AI tool need the same governance?
No. Controls should be proportionate to data sensitivity, patient exposure, clinical influence and potential harm, but every approved use still needs a clear purpose, owner and acceptable-use boundary.
Is human review enough to make an AI tool safe?
No. Human oversight is one control. It must be meaningful and sit alongside appropriate data, supplier, testing, security, clinical-safety, transparency and monitoring controls.
Who should own healthcare AI governance?
A senior accountable owner should be supported by operational, clinical, information-governance, security, technical and user expertise according to the use case. Responsibilities should be written and understood.